BPO 0.00% 0.3¢ bioprospect limited

bioprospect has success with hepatitis c project

  1. 1,269 Posts.
    BioProspect Limited (ASX: BPO) advises that it has received some extremely exciting results in relation to its collaboration with Apath LLC that is aimed at discovering novel compounds for the treatment of Hepatitis C Virus (HCV) and other viral diseases.
    Apath has advised BioProspect that it wishes to progress samples representing six species of native Australian plants to the next stage of its program. During the current screening phase, Apath indicated that they have been very pleased with the number of ‘hits’ it has obtained from the library supplied by BioProspect.
    BioProspect Chief Executive Officer Selwyn Snell said “These results demonstrate the uniqueness of BioProspect’s Natural Plant Extract Library. The potential of our library is unlimited.”
    HCV is one of the world’s most significant health threats and as acknowledged by the United States Centre for Disease Control, is predicted to exceed the US’ annual death toll from HIV/AIDS by 2011.
    The current worldwide market for HCV therapeutics is approximately US$1.7 billion annually, and is expected to grow to US$5 billion by 2010.
    Apath is a US-based drug discovery company with unique technologies and capabilities in viral molecular biology, with a focus on HCV and other RNA viruses.
 
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.